Linagliptin
- Generic Name
- Linagliptin
- Brand Names
- Glyxambi, Jentadueto, Tradjenta, Trajenta, Trijardy
- Drug Type
- Small Molecule
- Chemical Formula
- C25H28N8O2
- CAS Number
- 668270-12-0
- Unique Ingredient Identifier
- 3X29ZEJ4R2
- Background
Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin was approved by the FDA on May 2, 2011.
- Indication
Linagliptin is indicated for the treatment of type II diabetes in addition to diet and exercise. It should not be used to treat type I diabetes or in diabetic ketoacidosis. An extended-release combination product containing empagliflozin, linagliptin, and metformin was approved by the FDA in January 2020 for the improvement of glycemic control in adults with...
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
Study to Evaluate the Effect of Multiple Doses of Rifampicin on the Multiple-dose Pharmacokinetics of Linagliptin in Healthy Volunteers
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 16
- Registration Number
- NCT02183584
The Effect of Combination of Mosapride and DPP-4 Inhibitor on Plasma Concentration of Incretin Hormones
- Conditions
- Interventions
- First Posted Date
- 2014-07-02
- Last Posted Date
- 2017-11-29
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 12
- Registration Number
- NCT02180334
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Relative Bioavailability of BI 10773 and Linagliptin in Healthy Male Volunteers
- First Posted Date
- 2014-06-24
- Last Posted Date
- 2014-06-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 16
- Registration Number
- NCT02172222
Ascertainment of EMR-based Clinical Covariates Among Patients Receiving Oral and Non-insulin Injected Hypoglycemic Therapy
- First Posted Date
- 2014-05-16
- Last Posted Date
- 2017-02-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 166613
- Registration Number
- NCT02140645
- Locations
- 🇺🇸
Boehringer Ingelheim Investigational Site, Boston, Massachusetts, United States
Bioequivalence of a FDC Tablet of Linagliptin/Metformin (2.5mg/750mg) Extended Release in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2014-04-23
- Last Posted Date
- 2016-08-04
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 74
- Registration Number
- NCT02121509
- Locations
- 🇩🇪
1288.10.1 Boehringer Ingelheim Investigational Site, Ingelheim, Germany
Effect of Linagliptin on Insulin Sensitivity and Pancreatic Beta Cell Function in Patients With Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2014-03-27
- Last Posted Date
- 2014-04-08
- Target Recruit Count
- 30
- Registration Number
- NCT02097342
- Locations
- 🇮🇳
Postgraduate Institute of Medical Education & Research, Chandigarh, India
Safety Evaluation of Adverse Reactions in Diabetes
- Conditions
- Interventions
- First Posted Date
- 2014-03-20
- Last Posted Date
- 2018-02-07
- Lead Sponsor
- Charles University, Czech Republic
- Target Recruit Count
- 42
- Registration Number
- NCT02092597
- Locations
- 🇨🇿
General University Hospital, Prague, Czechia
Bioequivalence of a FDC Tablet of Linagliptin/Metformin (2.5mg/1000mg) Extended Release in Healthy Subjects.
- Conditions
- Interventions
- First Posted Date
- 2014-03-11
- Last Posted Date
- 2016-08-04
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 74
- Registration Number
- NCT02084056
- Locations
- 🇩🇪
1288.11.1 Boehringer Ingelheim Investigational Site, Biberach, Germany
Bioequivalence of a FDC Tablet of Linagliptin/Metformin (5mg/1000mg) Extended Release in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2014-03-11
- Last Posted Date
- 2016-08-04
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 68
- Registration Number
- NCT02084082
- Locations
- 🇩🇪
1288.9.1 Boehringer Ingelheim Investigational Site, Biberach, Germany
Effect of Linagliptin on Vascular Inflammation in Patients With Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2014-03-04
- Last Posted Date
- 2017-04-12
- Lead Sponsor
- RWTH Aachen University
- Target Recruit Count
- 4
- Registration Number
- NCT02077309
- Locations
- 🇩🇪
Department of Internal Medicine I, University Hospital, Aachen, Germany
🇳🇱Cardiovascular Research Institute Maastricht (CARIM), Maastricht, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.